Caribou Biosciences CRBU 深 滬
等待開盤 10-08 09:30:00 美东时间
0.6174
-0.518
-45.60%
華盛通- 最 高0.67
- 今 開0.636
- 成交量 3700.41万股
- 最 低 0.546
- 昨 收 1.135
- 總市值 6618.99万
- 52周最高 3.535
- 市盈率 靜 --
- 換手率 34.52%
- 52周最低 0.546
- 委 比 38.53%
- 總股本 1.07亿
- 歷史最高 32.645
- 量 比 18.73
- 振 幅 10.93%
- 歷史最低 0.546
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Brookline Capital Downgrades Caribou Biosciences to Hold
Brookline Capital analyst Leah Cann downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Hold.
10-07 23:06
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why
Caribou Biosciences Inc. (NASDAQ:CRBU) shares fell 35.07% to $0.74 in after-hours trading Tuesday after the company announced it is exploring strategic alternatives and plans to discontinue its two cell therapy programs. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical...
10-07 13:34
Caribou Biosciences Mulls Strategic Options To Maximize Shareholder Value; Intends To Discontinue Further Development Activities For Two Allogeneic CAR-T Cell Therapy Programs
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell ther...
10-07 04:07
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax reported business updates and first half 2026 financial results, including the appointment of Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer. The company has a cash runway into Q4 2029, following the completion of a public offering and royalty certificate buy-back. R&D expenses increased due to new indications and clinical trial advancements, while G&A and sales/marketing expenses also rose to support future...
09-21 20:05
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
08-15 02:25
Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $1.499 millio...
08-14 04:24
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences reported Q2 2026 financial results and business updates, highlighting clinical data for vispa-cel and CB-011. Vispa-cel demonstrated durable responses in 2L LBCL patients, with an 82% ORR and 67% CR rate. CB-011 showed deep responses in high-risk MM patients, achieving a 92% ORR and 83% CR rate. The company plans pivotal trials for vispa-cel and expects to report initial CB-011 dose expansion data in H2 2026. Financially, the ...
08-13 20:05
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Pharmaceuticals, Inc. ("Olema Oncology") announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. O’Byrne brings over 20 years of finance and global operations leadership in biotech and pharma. He previously served as CFO at Vir Biotechnology and Caribou Biosciences, leading financial and capital markets initiatives, including IPOs and acquisitions. Olema Oncology is advancing therapies for breast cancer, with palazestra...
08-13 11:00
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
